GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » Gross Profit

EVAX (Evaxion Biotech AS) Gross Profit : $3.30 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Evaxion Biotech AS Gross Profit?

Evaxion Biotech AS's gross profit for the three months ended in Sep. 2024 was $3.02 Mil. Evaxion Biotech AS's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was $3.30 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Evaxion Biotech AS's gross profit for the three months ended in Sep. 2024 was $3.02 Mil. Evaxion Biotech AS's Revenue for the three months ended in Sep. 2024 was $3.02 Mil. Therefore, Evaxion Biotech AS's Gross Margin % for the quarter that ended in Sep. 2024 was N/A%.

Evaxion Biotech AS had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage


Evaxion Biotech AS Gross Profit Historical Data

The historical data trend for Evaxion Biotech AS's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evaxion Biotech AS Gross Profit Chart

Evaxion Biotech AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial - - - - 0.07

Evaxion Biotech AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.07 0.05 0.15 3.02

Competitive Comparison of Evaxion Biotech AS's Gross Profit

For the Biotechnology subindustry, Evaxion Biotech AS's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evaxion Biotech AS's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evaxion Biotech AS's Gross Profit distribution charts can be found below:

* The bar in red indicates where Evaxion Biotech AS's Gross Profit falls into.



Evaxion Biotech AS Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Evaxion Biotech AS's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=0.073 - 0
=0.07

Evaxion Biotech AS's Gross Profit for the quarter that ended in Sep. 2024 is calculated as

Gross Profit (Q: Sep. 2024 )=Revenue - Cost of Goods Sold
=3.017 - 0
=3.02

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.30 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Evaxion Biotech AS's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as

Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=3.02 / 3.017
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Evaxion Biotech AS  (NAS:EVAX) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Evaxion Biotech AS had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage


Evaxion Biotech AS Gross Profit Related Terms

Thank you for viewing the detailed overview of Evaxion Biotech AS's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Evaxion Biotech AS Business Description

Traded in Other Exchanges
N/A
Address
Dr. Neergaards Vej 5f, Hoersholm, DNK, DK-2970
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.